Abstract
More than 200,000 patients are diagnosed with primary or metastatic brain tumors each year in the United States. Of these patients, 20% to 40% will develop seizures at presentation, and another 20% to 40% will require treatment for seizures during their illness. Although the use of antiepileptic drugs (AEDs) in patients who have had seizures seems reasonable, the issue of prophylactic AED use for patients who have not had a seizure is an intensely debated subject. The American Academy of Neurology released a position statement in May 2000 addressing the use of anticonvulsants in newly diagnosed brain tumor patients who have never had a seizure. After a review of the literature, including all trials showing class I evidence, multivariate analysis using calculated odds ratios failed to show a prophylactic benefit of preventing a first seizure versus the risk of side effects and recommended not using prophylactic anticonvulsants in newly diagnosed patients with brain tumor. Despite this recommendation, a recent survey of the American Association of Neurologic Surgeons revealed that most neurosurgeons still use anticonvulsants prophylactically in patients with brain tumor. This review mainly includes primary brain tumors, but most of the concepts are transferable to patients with metastatic tumors.
Similar content being viewed by others
References and Recommended Reading
Primary Brain Tumors in the United States: Statistical Report. Chicago, IL: Central Brain Tumor Registry of the United States; 1997–2001.
Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics. Cancer J Clin 1999, 49:8–31.
Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886–1893. Required reading for anyone prescribing anticonvulsants.
Sirven JI, Wingerchuk DM, Drazkowski JF, et al.: Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004, 79:1489–1494.
Sirven JI: Classifying seizures and epilepsy: a synopsis. Semin Neurol 2002, 22:237–246. Excellent review of seizure classification.
French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:401–409.
French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugs, II: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:401–409. Provides practice parameters to help guide decision making in treatment.
Kessler RC, Bavis RB, Foster DF, et al.: Long-term trends in the use of complimentary and alternative medical therapies in the United States. Ann Intern Med 2001, 135:262–268.
Eisenbery DM, Davis RB, Ettner SL, et al.: Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998, 280:1569–1575.
Hariharan S, Landol. J, More J, et al.: Alternative therapy use by malignant glioma patients: data from the glioma outcomes project. Neuro-oncol 2000, 2:268.
Chang SM, Parney IF, Haung MS, et al.: Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005, 293:557–564. This is an excellent up-to-date analysis of practice patterns for newly diagnosed high-grade gliomas from a multi-institutional study.
Verhoef MJ, Hagan N, Pelletier G, Forsyth P: Alternative therapy use in neurologic diseases: use in brain tumor patients. Neurology 1999, 52:617–622.
Plunkett M, Klein E, Alldredge B: Use of complimentary and alternative medicine products by patients with epilepsy. How common is it? Epilepsia 2004, 45(Suppl 7):149.
Khoi DT, Kossoff EH, Rubenstrein JE, et al.: Can you predict immediate, complete, and sustained response to the ketogenic diet? Epilepsia 2005, 46:580–582.
Nebeling LC, Miraldi F, Shurin SB, Lerner E: Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 1995, 14:202–208.
Cole AJ: Initial individualized selection of long-term anticonvulsants drugs by neurologists. Neurology 2004, 63(Suppl 4):S1-S2.
Vecht CJ, Wagner GL, Wilms EB: Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003, 30(Suppl 19):49–52.
Perry JR, Sawaka C: Add-on gabapentin for refractory seizures in patients with brain tumors. Can J Neurol Sci 1996, 23:128–131.
Newton HB, Goldlust S, Pearl D: Retrospective analysis of levetiracetam for the treatment of seizures in brain tumor patients. Neurology 2005, 64(Suppl 1):A47.
Larson SE, Sirven JI, Drazkowski JF, Zimmerman RS: Efficacy and tolerability of levetiracetam in patients with brain tumors and seizures. Epilepsia 2004, 45(Suppl 7):124.
Penovch PE, Dickens DL, Gates JR, et al.: Treating seizures due to brain neoplasms: rational new choices. Epilepsia 2004, 45(Suppl 7):311.
Wagner GL, Wilms EB, Van Donselaar CA, Vecht CHJ: Levetiracitam: preliminary experience in patients with primary brain tumors. Seizure 2003, 12:585–586.
Stevens GH, Vogelbaum MA, Suh JH, et al.: Levetiracetam use in brain tumor patients. Neurology 2005, 64(Suppl 1):A48.
Wrighton SA, Stevens JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992, 22:1–21.
Nelson DR, Koymans L, Kamataki T, et al.: P450 super family: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1–42.
Gilbert MR, Supko JG, Batchelor T, et al.: Phase I clinical trial and pharmacokinetics study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003, 9:2940–2949.
Fetell MR, Grossman SA, Fischer JD, et al.: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 1997, 15:3121–3128.
Bourg V, Lebrun C, Chichmahian RM, et al.: Nitrosoureacisplatinum based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001, 12:217–219.
Bittigua P, Sifringer M, Genz K, et al.: Antineoplastic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A 2002, 99:15089–15094.
Jaeckle K, Ballman K, Uhm J, et al.: Relationship of administration of enzyme-inducing anticonvulsants (EIAC) to survival in patients with glioblastoma: a North Central Cancer treatment Group (NCCTG) study. Neuro-oncol 2004, 6:376.
Chalifoux R, Elisevich K: Effect on ionizing radiation on partial seizures attributable to malignant cerebral tumors. Stereotact Funct Neurosurg 1996, 97:169–182.
Rogers L, Morris H, Lupica K: Effect of cranial irradiation on seizure frequency in adults with low grade astrocytomas and medically intractable epilepsy. Neurology 1993, 43:1599–1601.
Hwang SL, Lin CL, Lee KS, et al.: Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wein) 2004, 146:589–594.
Regis J, Bartolomei F, Rey M, et al.: Gamma knife surgery for mesial temporal lobe epilepsy. J Neurosurg 2000, 93(Suppl 3):141–146.
Regis J, Rey M, Bartolomei F, et al.: Gamma knife surgery in mesial temporal lobe epilepsy: a prospective multicenter study. Epilepsia 2004, 45:504–515.
Wyllie ER, Luders H, Morris HH III, et al.: Clinical outcome after complete or partial resection for intractable epilepsy. Neurology 1987, 37:1634–1641.
Berger MS, Ghatan S, Haglund MM, et al.: Low grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg 1993, 79:62–69.
Wen PY, Marks PW: Medical management of patients with brain tumors. Curr Opin Oncol 2002, 14:299–307.
Jooma R, Yeh HS, Privitera MD, Gartner M: Lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with complex partial seizures. J Neurosurg 1995, 83:231–236.
Labar D, Murphy J, Tecoma E: Vagus nerve stimulation for medication-resistant generalized epilepsy. EO4 Study Group Neurology 1999, 52:1510–1512.
Karceski S: Devices in the treatment of epilepsy. Semin Neurol 2002, 22:259–268.
Ng M, Devinsky O: Vagus nerve stimulation for refractory idiopathic generalized epilepsy. Seizure 2004, 13:176–178.
Wilder BJ: Vagal nerve stimulation. In Epilepsia: A Comprehensive Textbook. Edited by Engle JJr, Pedley TA. Philadelphia: Lippincott-Raven; 1997:1353–1358.
Fischer RS, Mirski M, Krauss G: Brain stimulation. In Epilepsy: A Comprehensive Textbook. Edited by Engle JJr, Pedley TA Philadelphia: Lippincott-Raven; 1997:1867–1875.
Fischer RS, Uematsu S, Kraus GL, et al.: Placebo-controlled pilot study of centromedian thalamic stimulation in treatment of intractable seizures. Epilepsia 1992, 33:841–851.
Bergey GK, Britton JW, Cuscino GD, et al.: Implementation of an external responsive neurostimulator in patients with intractable epilepsy undergoing intracranial seizure monitoring. Epilepsia 2002, 43(Suppl 7):191.
Kubota F, Kifune A, Shibata N, et al.: Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study. Epilepsy Res 1999, 33:93–97.
Hahn TJ, Birge SJ, Scara CR, et al.: Phenobarbital induced alterations in vit D metabolism. J Clin Invest 1972, 51:741–748.
Ensrund WE, Walczak TS, Blackwell T: Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004, 62:2051–2057.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stevens, G.H.J. Antiepileptic therapy in patients with central nervous system malignancies. Curr Neurol Neurosci Rep 6, 311–318 (2006). https://doi.org/10.1007/s11910-006-0024-9
Issue Date:
DOI: https://doi.org/10.1007/s11910-006-0024-9